New Delhi: Glenmark Pharma launches Nitric Oxide Nasal Spray (FabiSpray) in India for the treatment of adult patients with Covid-19 in partnership with SaNOtize.
Glenmark Pharmaceuticals Limited (Glenmark) and Canadian pharmaceutical company SaNOtize Research & Development Corp. today announced the launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.
Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.
Comments are closed.